Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Carcinoma, Transitional Cell × Trastuzumab × 30 days × Clear all

Sponsor

Conditions

Breast Neoplasms 21 Stomach Neoplasms 6 Neoplasms 5 Esophageal Neoplasms 5 Neoplasm Metastasis 4 Colorectal Neoplasms 4 Adenocarcinoma Of Esophagus 4 Triple Negative Breast Neoplasms 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 HER2-positive Breast Cancer 2 Carcinoma, Non-Small-Cell Lung 2 Brain Neoplasms 2 Adenocarcinoma 2 Uterine Cervical Neoplasms 1 Solid Tumors 1 Resectable HER2-positive Breast Cancer 1 Rectal Neoplasms 1 Pathologic Complete Response 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Meningeal Neoplasms 1 Malignant Solid Neoplasm 1 Hemangiosarcoma 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Gastric Cancer 1 HER2-positive Early Breast Cancer 1 Gastroesophageal Adenocarcinoma 1 Gallbladder Neoplasms 1 Endometrial Neoplasms 1

Interventions

pembrolizumab 15 enfortumab vedotin 10 Specimen Handling 9 Magnetic Resonance Spectroscopy 9 Nivolumab 7 Carboplatin 5 avelumab 4 Ipilimumab 4 Gemcitabine 4 Docetaxel 4 Cisplatin 4 sacituzumab govitecan 3 Paclitaxel 3 cabozantinib 2 Taxes 2 CTLA-4 Antigen 2 Biopsy 2 zimberelimab 1 zanidatamab 1 tazemetostat 1 soluble LAG-3 protein, human 1 sargramostim 1 sapanisertib 1 relatlimab 1 regorafenib 1 lenvatinib 1 eribulin 1 erdafitinib 1 durvalumab 1 dodecyl maltoside 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡